EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction

Akshee Batra, Xena Zheng, Dan Morgenstern-Kaplan, Carey C Thomson, Gilberto Lopes, Chinmay Jani

Frontiers in Cell and Developmental Biology · 20.07.2026 · 14

DOI: 10.3389/fcell.2026.1874565 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 20.07.2026. Verfasst von Akshee Batra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States. Die Arbeit nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid biopsy now provides minimally invasive access to tumor-derived genomic and epigenetic information across the lung cancer continuum, and its clinical role continues to expand. This review examines that role across cancer detection (screening and diagnosis), treatment monitoring (advanced-disease genotyping, minimal residual disease (MRD) assessment, and resistance profiling at progression), and clinical outcome prediction. Plasma-based genotyping is now well established in advanced non-small cell lung cancer (NSCLC), while circulating tumor DNA (ctDNA)-based MRD detection in the curative-intent setting has accumulated a substantial evidence base over the past 5 years. Cell-free DNA (cfDNA) methylation, fragmentomics, and circulating tumor RNA (ctRNA) are emerging as complementary modalities, particularly when tumor shedding is low. We also consider concordance between liquid and tissue biopsies, the use of cerebrospinal fluid (CSF) ctDNA in central nervous system (CNS)-involved disease, and the practical issues of cost, reimbursement, and access that shape clinical adoption. The current state of the field can be framed across three tiers of evidence, with established applications, applications under prospective evaluation, and applications not yet ready for routine clinical use. No multi-cancer early detection (MCED) test has shown a mortality benefit to date, and ctDNA-guided treatment changes in metastatic disease still lack randomized overall-survival data.

Schlagwörter

Stichwörter der Autor:innen

circulating tumor RNAcirculating tumor cell (CTC)liquid biopsylung cancermethylation and prognosis

Autor:innen und Institutionen

  • Department of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.
  • Department of Medicine, Mount Auburn Hospital, Beth Israel Lahey Health, Cambridge, MA, United States.
  • Department of Medicine, Harvard Medical School, Boston, MA, United States.

Zitieren

APA

Batra, A., Zheng, X., Morgenstern-Kaplan, D., Thomson, C. C., Lopes, G., & Jani, C. (2026). Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1874565

Vancouver

Batra A, Zheng X, Morgenstern-Kaplan D, Thomson CC, Lopes G, Jani C. Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1874565

BibTeX
@article{Batra2026,
  author = {Batra, Akshee and Zheng, Xena and Morgenstern-Kaplan, Dan and Thomson, Carey C and Lopes, Gilberto and Jani, Chinmay},
  title = {Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2026},
  volume = {14},
  doi = {10.3389/fcell.2026.1874565}
}
Kostenlos starten →